

## **COLOCOMB: Combinatory and targeted nanomedicines for the treatment of advanced colorectal cancer.**

**ADRESSED PATHOLOGY:** Colorectal Cancer

### **PARTICIPANTS:**

—Simo Schwartz Jr. /Ibane Abasolo. CIBBIM-Nanomedicine.  
Hospital Vall d'Hebron.

—Fernando Albericio/Miriam Royo. PCB-UB

—M.-Pilar Marco/Roger Galve. Nb4D-CSIC

### **CLINICAL GROUPS:**

—Santiago Ramon y Cajal. Hospital Vall D'Hebron.

—Manel Armengol. Hospital Vall d'Hebron.

### **GENERAL OBJECTIVES:**

The aim of the project is to first fully validate new nanosystems (developed in an anterior project), and secondly develop even more specific nanocarriers, with a higher efficacy for the treatment of colorectal cancer. For it, three research lines will be developed: i) Combination therapy: evaluation of nanosystems releasing two specific drugs simultaneously within the tumours, ii) Targeted release/accumulation: in vitro and in vivo studies of the efficacy of PGA drug delivery systems with a MMP7-sensitive linker iii) CSC specificity: testing of novel drug delivery systems targeting surface antigens (CD133) over expressed in colon cancer stem cells (CSC)